RECURRENT HEAD AND NECK CANCER
Clinical trials for RECURRENT HEAD AND NECK CANCER explained in plain language.
Never miss a new study
Get alerted when new RECURRENT HEAD AND NECK CANCER trials appear
Sign up with your email to follow new studies for RECURRENT HEAD AND NECK CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise for tough head and neck cancer
Disease control OngoingThis study tests whether adding ramucirumab to pembrolizumab works better than pembrolizumab alone for people with advanced head and neck cancer that has come back or spread. About 37 adults with PD-L1 positive cancer will take part. The goal is to see if the combination shrinks …
Matched conditions: RECURRENT HEAD AND NECK CANCER
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 17, 2026 03:13 UTC
-
New combo therapy aims to boost survival in hard-to-treat head and neck cancer
Disease control OngoingThis phase 3 study tests whether adding an experimental immunotherapy (PDS0101) to standard pembrolizumab helps people with advanced HPV16-positive head and neck cancer live longer or delay tumor growth. About 252 adults whose cancer has spread or returned and cannot be removed b…
Matched conditions: RECURRENT HEAD AND NECK CANCER
Phase: PHASE3 • Sponsor: PDS Biotechnology Corp. • Aim: Disease control
Last updated May 13, 2026 15:58 UTC